The First Years After a Type 2 Diabetes Diagnosis May Matter More Than We Thought

For years, clinicians have known that blood glucose control early in type 2 diabetes can influence the risk of complications later in life. Now, new research raises another important question: could the first few years of glycemic control also be related to future cancer risk? A large cohort study found an association between early hyperglycemia and cancer risk, with higher HbA1c exposure soon after diagnosis appearing more strongly associated with later cancer than similar exposure occurring years afterward. However, the findings are observational and do not prove that lowering HbA1c prevents cancer.

Table of Contents

• What the new study found
• Why the timing of hyperglycemia may matter
• What the results mean for diabetes care
• Important limitations of the research
• Conclusion
• Frequently asked questions

What the Early Hyperglycemia and Cancer Risk Study Found

The 2026 study, published in Diabetologia, analyzed a territory-wide cohort of 52,926 Hong Kong Chinese adults with newly diagnosed type 2 diabetes. Researchers examined HbA1c levels over time and compared glycemic exposure with the later development of cancer.

Among 49,978 participants included in the analysis of overall glycemic burden, researchers recorded 1,758 cancer events during a median follow-up of 6.1 years. Lung, colorectal, and liver cancers were among the most commonly recorded cancers.

Importantly, cancer risk rose as average HbA1c increased. Each 1 percentage point increase in time-weighted mean HbA1c was associated with a 27% relative increase in the hazard of cancer at any site after statistical adjustment for several potential confounding factors.

The pattern was also noticeable when researchers focused on the first years following a diabetes diagnosis. During the first two years, an average HbA1c of 7.0% or higher was generally associated with greater subsequent cancer risk than an HbA1c below 7.0%. However, estimates varied across HbA1c groups, and not every individual comparison reached statistical significance.

These results add cancer to the growing discussion around the possible long-term consequences of early glycemic exposure. Still, association should not be confused with causation.

Why Early Glycemic Exposure May Be Especially Important

One of the most interesting findings involved timing. Earlier periods of elevated HbA1c appeared to contribute more strongly to later cancer risk than elevated values occurring later in the course of diabetes.

This pattern resembles the concept of a glycemic “legacy effect.” In diabetes research, that term usually describes how glucose control during the early years of the disease may influence cardiovascular and microvascular outcomes many years later. Previous studies have found that early glycemic control can have lasting associations with complications even after later HbA1c levels are taken into account.

The newer cancer study suggests a similar pattern may deserve investigation in oncology. For example, participants with better glycemic management early after diagnosis showed a lower cancer risk than people whose glucose control improved later, even when their overall glycemic exposure was comparable.

Researchers proposed several possible biological explanations. Chronic hyperglycemia may contribute to oxidative stress, inflammation, metabolic changes, and cellular signaling pathways associated with tumor development. Insulin resistance and hyperinsulinemia may also play roles.

However, these mechanisms remain complex. The study cannot determine which pathway, if any, directly caused the observed cancer outcomes. Therefore, the relationship between early hyperglycemia, diabetes, and cancer should be viewed as an important research signal rather than proof of a direct biological pathway.

What These Findings Mean for Type 2 Diabetes Care

The findings reinforce an already important principle in diabetes management: the period soon after diagnosis deserves attention. Early glucose management may have consequences that extend well beyond the next HbA1c test.

That does not mean every patient should pursue the lowest possible HbA1c. Glycemic targets should remain individualized according to factors such as age, medications, cardiovascular and kidney health, hypoglycemia risk, life expectancy, and personal treatment goals.

In addition, cancer prevention involves much more than glucose control. Smoking, obesity, alcohol use, physical activity, diet, age, genetics, and recommended cancer screening can all influence risk.

For clinicians, the study may provide another reason to address sustained hyperglycemia early rather than allowing elevated HbA1c to persist for years. At the same time, treatment decisions should continue to follow evidence-based diabetes guidelines rather than using these observational cancer findings as a new HbA1c target.

Patients who are concerned about their glucose levels or individual cancer risk should discuss both with their healthcare professional. Diabetes management is most effective when treatment goals reflect the whole patient rather than a single laboratory number.

Why the Study Does Not Prove That Lowering A1C Prevents Cancer

The distinction between association and causation is especially important here. This was an observational cohort study, not a randomized trial assigning people to different glucose targets.

Although researchers adjusted for factors including age, sex, smoking, alcohol use, BMI, blood pressure, lipid measures, cardiovascular disease, kidney disease, and diabetes medications, unmeasured differences could still have influenced the results.

Furthermore, the population consisted of Chinese adults in Hong Kong. The general pattern may apply elsewhere, but the exact risk estimates should not automatically be assumed to represent every racial, ethnic, or geographic population.

Previous randomized studies of intensive versus standard glycemic management have also not established that intensive glucose lowering reduces cancer incidence. Therefore, it would be premature to conclude that reducing HbA1c by a certain amount will directly prevent cancer.

Instead, the findings support further research into whether the timing and duration of hyperglycemia have long-lasting effects beyond traditional diabetes complications.

Conclusion

The first years following a type 2 diabetes diagnosis may carry more long-term importance than previously recognized. In this large cohort, greater glycemic exposure was associated with higher subsequent cancer risk, and hyperglycemia occurring earlier after diagnosis appeared to have a stronger association than later exposure.

Still, the study cannot show that high glucose directly causes cancer or that lowering HbA1c prevents it. For now, the strongest clinical message remains familiar: identify hyperglycemia early, individualize treatment, avoid prolonged poor glycemic control when safely possible, and continue established cancer prevention and screening practices.

Frequently Asked Questions

1. Does high blood sugar cause cancer?
   Research has found associations between hyperglycemia and certain cancers, but observational studies cannot prove that elevated glucose directly causes cancer. Many metabolic, lifestyle, and genetic factors may contribute.
2. Why might early blood glucose control matter?
   Some evidence suggests that glycemic exposure during the first years after a type 2 diabetes diagnosis may have lasting associations with later health outcomes. This phenomenon is often discussed as a glycemic legacy effect.
3. Does lowering HbA1c reduce cancer risk?
   The new study does not prove that lowering HbA1c prevents cancer. Randomized trials would be needed to determine whether deliberately reducing glucose exposure leads to fewer cancers.
4. Should people with diabetes aim for an HbA1c below 7%?
   Not necessarily. HbA1c targets should be individualized. Many people have a target near 7%, but the appropriate goal depends on overall health, medications, hypoglycemia risk, age, and other clinical factors.
5. Should cancer screening change after a type 2 diabetes diagnosis?
   This study alone does not establish new cancer-screening recommendations. Patients should continue age- and risk-appropriate screening and discuss individual risk factors with their healthcare professional.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.